Group items matching

in title, tags, annotations or url

This Funding Opportunity Announcement (FOA) encourages Small Business Innovative Research (SBIR) grant applications from small business concerns (SBCs) to address problems associated with the methods of collection, bioassay, isolation, purification, de-replication, yield, and supply that hamper the full utilization of natural products. 

This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) Fast Track grant applications that propose to test and/or validate novel, state-of-the-art candidate biomarker platforms for predicting the onset and progression of inflammatory diseases of interest to the NIAMS and for determining the pharmacodynamics, safety and/or efficacy of therapeutic agents targeting those diseases.

This Funding Opportunity Announcement (FOA) supports Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that will develop and/or validate devices or electronic systems that can: 1) monitor biologically- or behaviorally-based processes applicable to mind and body interventions or 2) be used to assist in optimizing the practice or increasing the efficacy of mind and body interventions.  The applications should: 1) lead to the development of new technologies, 2) adapt existing innovative technologies, devices and/or electronic systems, 3) repurpose existing devices and electronic systems, or 4) conduct testing of single or combined components of an integrated, long term, automated, wearable monitoring, stimulation device or electronic system in order to monitor or enhance the mechanistic processes or functional outcomes of mind and body interventions. For the purposes of this FOA, mind and body interventions are defined as non-pharmacological approaches that include mind/brain focused interventions (e.g., meditation, hypnosis), body-based approaches (e.g., acupuncture, massage, spinal manipulation/mobilization), or combined mind and body meditative movement approaches (e.g., yoga, tai-chi, qigong).  

This funding opportunity announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) to develop and validate next-generation single cell analysis technologies and tools. The purpose is to foster the commercialization of innovative single cell analysis technologies for their broad use in biomedical research. The novel single-cell analysis technologies will aid in obtaining a fine-grained and dynamic view of heterogeneous cellular states and intercellular interactions, thereby providing new mechanistic insight into biological processes in health and disease. Applications should define the current state of technologies and tools as a benchmark against which the new approach(es) will be measured. The new approach(es) should provide substantially improved performance in sensitivity, selectivity, spatiotemporal resolution, scalability, multiplexing capability, or non-destructive analysis of molecular or functional measures of single cells.

The purpose of this funding opportunity announcement (FOA) is to encourage applications to the newly authorized Direct-to-Phase II SBIR grant mechanism.  Applications are invited from eligible United States small business concerns (SBCs) that have demonstrated the scientific and technical merit and feasibility of the prototype stage of developing a biomedical technology that has commercial potential, R&D that is characteristic of Phase-I (R43) SBIR projects.  The Direct-to-Phase II grant mechanism is intended to facilitate SBIR-type R&D, to expand R&D opportunities for applicant small business concerns (SBCs), and to enhance the pace of technology development and commercialization.   

This Funding Opportunity Announcement (FOA) solicits Small Business Innovative Research (SBIR) grant applications from small business concerns (SBCs) to develop novel technologies to expand the capability for molecular analyses of banked frozen or formalin-fixed, paraffin-embedded tissues. In addition, there is a need for improved tissue fixatives and preservation methods that maintain histologic features while preserving high quality DNA, RNA, protein and small molecules in archived tissue from rodent and human studies.

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research for commercial development of novel cancer-relevant technologies. The proposed research projects are expected to focus on the development of highly-innovative technologies that improve molecular and/or cellular analysis of cancer with a significant likelihood for either overcoming persistent challenges or obstacles or opening entirely new fields for cancer research or clinical care. Applications should specify milestones relevant to both the development and commercialization of these technologies. This FOA complements the goals of the NCI's Innovative Molecular Analysis Technologies (IMAT) program by facilitating the path towards technology commercialization. Prior participation in the IMAT Program is not required for eligibility for this FOA. Applications are expected to indicate the significant attributes and advantages of the proposed technology over currently available technologies and conventional approaches.

This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress toward integrated long term glucose regulated insulin/pancreatic hormones delivery systems (artificial pancreas).

The purpose of The GreenPal Small Business Scholarship is to assist a motivated, driven student and future business leader. We believe that the generation of today's students are the future employers of tomorrow. The future of our county will be forged by the entrepreneurial spirit of today's generation. If you currently run a small business while attending college or have a small business idea to start while you plan to attend college, see below for the instructions and criteria for applying for the GreenPal scholarship. 1. DEADLINE for scholarship applications is May 30th, 2014. 2. Refer to criteria below for eligibility requirements. 3. Refer to application process below for a list of the supporting documents needed (i.e., evidence of GPA.) Incomplete applications will not be considered. 4. Submissions are to be submitted through the online application process below. 5. Scholarship winner will be announced June 15th, 2014. 6. This is an evergreen scholarship and will be renewed and funded each year by GreenPal.

This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications that propose to develop a product, process or service for commercialization with the aim of reducing disparities in healthcare access and health outcomes. Appropriate technologies should be effective, affordable, culturally acceptable, and deliverable to racial/ethnic minorities, low-income and rural populations.

We are pleased to announce that the new OARS website is up and running (although the new Research Compliance and Undergraduate Research sections are still in development).   If you haven't had a chance to check it out yet, we hope you will soon.  Once you've visited, we'd be grateful if you'd give us five minutes of your time to let us know how we're doing by completing a brief eight-question survey at https://miamioh.qualtrics.com/SE/?SID=SV_erhRsEFwwWVP6m1 Finally, don't forget to update any bookmarks you may have to material on our old website!

This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. Projects proposed in response to this FOA must be applicable to one of the following areas: (1) cancer therapeutics; (2) cancer imaging technologies, interventional devices, and in vivo diagnostics; or (3) in vitro and ex vivo cancer diagnostics and prognostics. The purpose of this FOA is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This FOA is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services.  Consistent with the goals of this funding initiative and as required by the SF424 instructions for all Phase II SBIR applications, applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required.  

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop and translate medical technologies aimed at reducing disparities in healthcare access and health outcomes.  Appropriate medical technologies should be effective, affordable, culturally acceptable, and deliverable to those who need them.  Responsive grant applications must involve a formal collaboration with a healthcare provider or other healthcare organization serving one or more health disparity populations during Phase I and Phase II.

This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications that propose to develop a product, process or service for commercialization with the aim of reducing disparities in healthcare access and health outcomes. Appropriate technologies should be effective, affordable, culturally acceptable, and deliverable to racial/ethnic minorities, low-income and rural populations.

The Small Business Liability Relief and Brownfields Revitalization Act ("Brownfields Law", P.L. 107-118) requires the U.S. Environmental Protection Agency (EPA) to publish guidance to assist applicants in preparing proposals for grants to assess and clean up brownfield sites. EPA's Brownfields Program provides funds to empower states, communities, tribes, and nonprofits to prevent, inventory, assess, clean up, and reuse brownfield sites. EPA provides brownfields funding for three types of grants: 1. Brownfields Assessment Grants - provides funds to inventory, characterize, assess, and conduct planning (including cleanup planning) and community involvement related to brownfield sites. 2. Brownfields Revolving Loan Fund (RLF) Grants - provides funds for a grant recipient to capitalize a revolving fund and to make loans and provide subgrants to conduct cleanup activities at brownfield sites. 3. Brownfields Cleanup Grants - provides funds to conduct cleanup activities at a specific brownfield site owned by the applicant. Under these guidelines, EPA is seeking proposals for Assessment Grants only. If you are interested in requesting funding for Cleanup Grants, please refer to announcement EPA-OSWER-OBLR-14-08 (Cleanup Grant guidelines) posted separately on www.grants.gov and www.epa.gov/brownfields. Note: A solicitation for new Revolving Loan Fund Grants will not be issued in FY15. EPA expects to solicit requests from existing, high performing RLF grantees 2 through a Federal Register notice for supplemental RLF funding in early 2015.

This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications that propose to develop a product, process or service for commercialization with the aim of reducing disparities in healthcare access and health outcomes. Appropriate technologies should be effective, affordable, culturally acceptable, and deliverable to racial/ethnic minorities, low-income and rural populations.

This funding opportunity announcement (FOA) encourages applications from small business concerns (SBCs) for Small Business Technology Transfer (STTR) projects to develop novel tools and devices to improve handling of laboratory animals, to ease the management of animal facilities, and to enhance experiments which use animal models. The intent is to facilitate the development and implementation of tools and devices to directly benefit the welfare of research animals, and to advance equipment to improve infrastructure and environmental conditions of animal facilities that support biomedical and bio-behavioral research.

Despite the availability of increasingly effective treatment modalities, including insulin analogues, continuous glucose monitors (CGMs), and continuous subcutaneous insulin infusion (CSII) devices, a substantial proportion of patients with type 1 diabetes (T1D) cannot achieve adequate glycemic control and avoid acute complications such as hypoglycemia.  NIDDK has long supported this area of research, especially through small business projects, and this support has contributed substantially to the development of new devices that are increasingly used in clinical practice.  Nonetheless, the approved devices and current technologies still have significant limitations, and it is important to put renewed emphasis on the creation of the next generation of devices that will further the goals of relieving patients of the burden of diabetes self-management and achieving daily euglycemia to prevent acute and chronic complications. However, given the pace of technical progress in this field and the substantial room for improvement in reliability, accuracy, and patient burden of current devices, NIDDK considers it important to continue supporting research in this field. This FOA is intended to support cutting edge research conducted by small business leading to the development of innovative technologies that may advance progress toward an integrated, long term, wearable/implantable, glucose regulated open and closed loop insulin/pancreatic hormone delivery systems.  This announcement has two main purposes: a) promote technical innovation and b) pre-clinical testing of single or combined components of open and closed loop systems

This Funding Opportunity Announcement (FOA) solicits Phase I (R43) Small Business Innovative Research (SBIR) grant applications from small business concerns (SBCs) to develop and/or adapt novel technologies to enable the characterization of human exposures to engineered nanomaterials (ENMs) and to monitor or assess ENMs in diverse media ranging from biological samples to air and water.  

Through its fellowships and travel grants, the Lemelson Center for the Study of Invention and Innovation supports research projects that present creative approaches to the study of invention and innovation in American society. Projects may include (but are not limited to) historical research and documentation projects resulting in dissertations, publications, exhibitions, educational initiatives, documentary films, or other multimedia products.